[EN] ARYLSULFONAMIDE DERIVATIVES AS MGLUR4 NEGATIVE ALLOSTERIC MODULATORS<br/>[FR] DÉRIVÉS D'ARYLSULFONAMIDE EN TANT QUE MODULATEURS ALLOSTÉRIQUES NÉGATIFS DE MGLUR4
申请人:HOFFMANN LA ROCHE
公开号:WO2021028512A1
公开(公告)日:2021-02-18
The present invention provides new arylsulfonamide compounds having the general formula (I), wherein L, R1, R2, R3 and R4are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as mGLUR4 negative allosteric modulators.
The present invention relates to sulfonamide compounds of formula (I) and formula (II), or a pharmaceutically acceptable salt thereof. The present sulfonamide compounds are useful non-systemic TGR5 agonists that can be used to treat diabetic diseases in human. The present invention provides a pharmaceutical composition containing sulfonamide compounds of formula (I) and formula (II) and a method of making as well as a method of using same in treating patients inflicted with metabolic disorders by administering same. The compounds of the present invention may be used in combination with additional anti-diabetic drugs.
[EN] NOVEL NON-SYSTEMIC TGR5 AGONISTS<br/>[FR] NOUVEAUX AGONISTES DE TGR5 NON SYSTÉMIQUES
申请人:VENENUM BIODESIGN LLC
公开号:WO2018005801A3
公开(公告)日:2018-02-01
ARYLSULFONAMIDE DERIVATIVES AS MGLUR4 NEGATIVE ALLOSTERIC MODULATORS
申请人:F. Hoffmann-La Roche AG
公开号:EP4013495A1
公开(公告)日:2022-06-22
NOVEL NON-SYSTEMIC TGR5 AGONISTS
申请人:Venenum Biodesign, LLC
公开号:US20200308122A1
公开(公告)日:2020-10-01
The present invention relates to sulfonamide compounds of formula (I) and formula (II), or a pharmaceutically acceptable salt thereof. The present sulfonamide compounds are useful non-systemic TGR5 agonists that can be used to treat diabetic diseases in human. The present invention provides a pharmaceutical composition containing sulfonamide compounds of formula (I) and formula (II) and a method of making as well as a method of using same in treating patients inflicted with metabolic disorders by administering same. The compounds of the present invention may be used in combination with additional anti-diabetic drugs.